行情

OTIC

OTIC

Otonomy
NASDAQ

实时行情|Nasdaq Last Sale

2.490
+0.020
+0.81%
已收盘, 16:00 12/13 EST
开盘
2.480
昨收
2.470
最高
2.510
最低
2.430
成交量
8.27万
成交额
--
52周最高
3.155
52周最低
1.500
市值
7,656.76万
市盈率(TTM)
-1.6399
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

OTIC 新闻

  • 收盘:关注贸易关系进展 纳指标普创新高
  • 新浪美股.1小时前
  • 因为用了这三个词 “版权狂魔”迪士尼被告了
  • 新浪美股.2小时前
  • 英国豪车制造商阿斯顿马丁与投资者会谈 评估融资
  • 新浪美股.3小时前
  • 美石油钻井数增加4座 结束连降但16周内已减少107座
  • FX168.4小时前

更多

所属板块

生物技术和医学研究
-0.88%
制药与医学研究
-0.07%

热门股票

名称
价格
涨跌幅

OTIC 简况

Otonomy, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company's product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase. OTO-104 is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Meniere's disease and other inner ear conditions. OTO-311 is a sustained-exposure formulation of the N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine in development for the treatment of tinnitus. It also has various other product candidates, which target sensorinerual hearing loss, including age-related hearing loss, also known as presbycusis.
展开

Webull提供Otonomy Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。